Preparing the trial collection…
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Search publications
Alerts and app
Email alertsPsilocybin Research MCP

Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Anxiety trial landscape

Psilocybin Clinical Trials for Anxiety

Review registry-listed psilocybin studies whose condition fields explicitly include anxiety, with current status, phase, enrollment, sites, and source links.

Explore this trial map All recruiting trials

Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.

20matching trials
7currently recruiting
23registry-listed sites

Registry facts checkedNov 5, 2026 02:25 UTC

Live registry synthesis

Status, geography, and study phase

Anxiety can be a primary condition or part of a broader clinical context. This collection preserves the registered condition labels so users can distinguish populations and protocols.

Recruitment status

  1. Recruiting7
  2. Completed4
  3. Active, not recruiting3
  4. Withdrawn3
  5. Not yet recruiting2
  6. Unknown status1

Leading countries

  1. United States11
  2. Switzerland3
  3. Canada2
  4. Jamaica1

Trial phases

  1. Phase 217
  2. Phase 13
  3. Early Phase 11
Interactive map

Explore matching study locations

The map opens with this collection’s filter applied. Its controls can further narrow status, phase, condition, country, intervention, and dates.

Open full map
Server-rendered source index

20 matching registry records

Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.

RecruitingNCT06200155

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

M.D. Anderson Cancer Center

Conditions
Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
Phase
Phase 2
Enrollment
48 estimated
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Registry updated
2026-11-03
Open registry recordDatabase record
RecruitingNCT06801041

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

M.D. Anderson Cancer Center

Conditions
Depression · Anxiety · Cancer
Phase
Phase 2
Enrollment
20 estimated
Locations
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Registry updated
2026-11-03
Open registry recordDatabase record
Not yet recruitingNCT07909408

Psilocybin FCR Early-Stage Breast Cancer

NYU Langone Health

Conditions
Early-stage Breast Cancer · Fear of Cancer Recurrence · Anxiety · Depression
Phase
Phase 2
Enrollment
100 estimated
Locations
University of Colorado Anschutz Medical Campus (CUAMC), Aurora, Colorado, United States · NYU Langone Heath, New York, New York, United States
Registry updated
2026-11-02
Open registry recordDatabase record
RecruitingNCT06442423

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

Yale University

Conditions
Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms
Phase
Phase 1
Enrollment
50 estimated
Locations
Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
Registry updated
2026-10-30
Open registry recordDatabase record
Active, not recruitingNCT07336238

A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

University of Washington

Conditions
Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
Phase
Phase 2
Enrollment
16 actual
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Registry updated
2026-10-29
Open registry recordDatabase record
RecruitingNCT06820723

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

Ohio State University

Conditions
Depression · Anxiety · Major Depressive Disorder
Phase
Phase 2
Enrollment
40 estimated
Locations
The Ohio State University Department of Psychiatry, Columbus, Ohio, United States
Registry updated
2026-10-20
Open registry recordDatabase record
CompletedNCT04932434

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

Joshua Woolley, MD, PhD

Conditions
Parkinson Disease · Depression · Anxiety
Phase
Phase 2
Enrollment
12 actual
Locations
University of California, San Francisco, San Francisco, California, United States
Registry updated
2026-09-03
Open registry recordDatabase record
RecruitingNCT06899165

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

Rachel Yehuda

Conditions
Psychological Stress · Depression · Anxiety
Phase
Phase 2
Enrollment
100 estimated
Locations
The Parsons Research Center for Psychedelic Healing, New York, New York, United States
Registry updated
2026-08-13
Open registry recordDatabase record
RecruitingNCT06969170

A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

Claudio N Soares

Conditions
Generalized Anxiety Disorder (GAD)
Phase
Phase 2
Enrollment
50 estimated
Locations
Kingston General Health Research Institute, Kingston, Ontario, Canada
Registry updated
2026-08-12
Open registry recordDatabase record
Active, not recruitingNCT04754061

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial

Ottawa Hospital Research Institute

Conditions
Depression, Anxiety · Distress, Emotional
Phase
Phase 1 · Phase 2
Enrollment
20 estimated
Locations
The Ottawa Hospital, Ottawa, Ontario, Canada · Bruyere Continuing Care, Ottawa, Ontario, Canada
Registry updated
2026-07-10
Open registry recordDatabase record
Not yet recruitingNCT07565909

A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

University of Washington

Conditions
Depression · Anxiety
Phase
Phase 2
Enrollment
72 estimated
Locations
No mapped site reported
Registry updated
2026-05-04
Open registry recordDatabase record
RecruitingNCT05883540

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

University Hospital, Basel, Switzerland

Conditions
Palliative Care · Pain · Anxiety · Depression
Phase
Phase 2
Enrollment
60 estimated
Locations
University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland · University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, Switzerland · Spital Uster AG, Division of Internal Medicine, Uster, Switzerland · +1 more
Registry updated
2026-04-29
Open registry recordDatabase record
Active, not recruitingNCT07164287

Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment

University Hospital, Geneva

Conditions
Major Depressive Disorder (MDD) · Anxiety Disorders · Substance Use Disorder (SUD) · PTSD - Post Traumatic Stress Disorder
Phase
Phase not reported
Enrollment
376 estimated
Locations
Geneva University Hospital, Geneva, Switzerland
Registry updated
2025-10-02
Open registry recordDatabase record
CompletedNCT00302744

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Conditions
Anxiety
Phase
Phase 1 · Phase 2
Enrollment
12 actual
Locations
Harbor-UCLA Medical Center, Torrance, California, United States
Registry updated
2025-03-13
Open registry recordDatabase record
Unknown statusNCT06444243

A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder

University of Sydney

Conditions
Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
Phase
Phase 2
Enrollment
90 estimated
Locations
No mapped site reported
Registry updated
2024-06-10
Open registry recordDatabase record
WithdrawnNCT00979693

Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.

Multidisciplinary Association for Psychedelic Studies

Conditions
Anxiety · Stage IV Melanoma
Phase
Phase 2
Enrollment
0 actual
Locations
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Registry updated
2023-12-26
Open registry recordDatabase record
WithdrawnNCT05252598

Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study

Optimi Health Corporation

Conditions
Mood Disturbance · Mood Change · Sleep Disturbance · Drug Effect
Phase
Early Phase 1
Enrollment
0 actual
Locations
No mapped site reported
Registry updated
2023-03-20
Open registry recordDatabase record
WithdrawnNCT04989972

Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults

Wake Network, Inc.

Conditions
Anxiety and Depression
Phase
Phase 2
Enrollment
0 actual
Locations
FMS Department of Psychiatry, Kingston, Jamaica
Registry updated
2022-06-30
Open registry recordDatabase record
CompletedNCT03153579

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study

University Hospital, Basel, Switzerland

Conditions
Patients · Anxiety Disorders
Phase
Phase 2
Enrollment
46 actual
Locations
University Hospital Basel, Basel, Canton of Basel-City, Switzerland · Private Practice P.Gasser, Solothurn, Canton of Solothurn, Switzerland
Registry updated
2021-12-22
Open registry recordDatabase record
CompletedNCT00465595

Psychopharmacology of Psilocybin in Cancer Patients

Johns Hopkins University

Conditions
Depressive Symptoms · Anxiety · Cancer
Phase
Phase 2
Enrollment
56 actual
Locations
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States
Registry updated
2018-07-19
Open registry recordDatabase record
Related research views

Move between curated condition, country, phase, and recruiting views without losing direct source provenance.

Recruitment

Conditions

Countries

Phases

Method and accountability

How this collection is maintained

Automatic refresh: counts, facets, records, and the map update from the database after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.

Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.

Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.